Arrowhead Pharmaceuticals, Inc. (0HI3.L)
USD 21.69
(-2.58%)
USD 21.69
(-2.58%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -1.91 USD | -14.97% |
| 2022 | -1.67 USD | -22.79% |
| 2021 | -1.36 USD | -61.9% |
| 2020 | -0.84 USD | -216.67% |
| 2019 | 0.72 USD | 210.77% |
| 2018 | -0.65 USD | -38.3% |
| 2017 | -0.47 USD | 64.93% |
| 2016 | -1.34 USD | 16.25% |
| 2015 | -1.60 USD | -28.0% |
| 2014 | -1.25 USD | 3.85% |
| 2013 | -1.30 USD | 31.58% |
| 2012 | -1.90 USD | -331.82% |
| 2011 | -0.44 USD | 51.11% |
| 2010 | -0.90 USD | 78.92% |
| 2009 | -4.27 USD | 38.21% |
| 2008 | -6.91 USD | 17.25% |
| 2007 | -8.35 USD | -40.34% |
| 2006 | -5.95 USD | -127.97% |
| 2005 | -2.61 USD | -38.83% |
| 2004 | -1.88 USD | -652.0% |
| 2003 | -0.25 USD | 99.23% |
| 2002 | -32.47 USD | -25.03% |
| 2001 | -25.97 USD | -33.32% |
| 2000 | -19.48 USD | -120.0% |
| 1999 | 97.40 USD | 1058.66% |
| 1998 | -10.16 USD | 94.21% |
| 1997 | -175.33 USD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q3 | -1.38 USD | -35.29% |
| 2024 Q1 | -1.24 USD | -21.57% |
| 2024 Q2 | -1.02 USD | 17.74% |
| 2023 Q1 | -0.39 USD | 51.85% |
| 2023 Q2 | 0.46 USD | 217.95% |
| 2023 Q4 | -1.02 USD | -6.25% |
| 2023 FY | - USD | -14.97% |
| 2023 Q3 | -0.96 USD | -308.7% |
| 2022 Q4 | -0.81 USD | -20.9% |
| 2022 Q2 | 0.42 USD | 170.0% |
| 2022 Q1 | -0.60 USD | 1.64% |
| 2022 FY | - USD | -22.79% |
| 2022 Q3 | -0.67 USD | -259.52% |
| 2021 Q4 | -0.61 USD | -110.34% |
| 2021 FY | - USD | -61.9% |
| 2021 Q1 | -0.20 USD | 57.45% |
| 2021 Q2 | -0.26 USD | -30.0% |
| 2021 Q3 | -0.29 USD | -11.54% |
| 2020 Q3 | -0.13 USD | 35.0% |
| 2020 Q4 | -0.47 USD | -261.54% |
| 2020 Q2 | -0.20 USD | -627.27% |
| 2020 FY | - USD | -216.67% |
| 2020 Q1 | -0.03 USD | -122.92% |
| 2019 Q1 | 0.13 USD | 208.33% |
| 2019 Q3 | 0.21 USD | -16.0% |
| 2019 Q4 | 0.12 USD | -42.86% |
| 2019 Q2 | 0.25 USD | 92.31% |
| 2019 FY | - USD | 210.77% |
| 2018 Q3 | -0.18 USD | 0.0% |
| 2018 FY | - USD | -38.3% |
| 2018 Q4 | -0.12 USD | 33.33% |
| 2018 Q2 | -0.18 USD | 0.0% |
| 2018 Q1 | -0.18 USD | -28.57% |
| 2017 Q1 | -0.17 USD | 45.16% |
| 2017 FY | - USD | 64.93% |
| 2017 Q2 | -0.08 USD | 52.35% |
| 2017 Q4 | -0.14 USD | -89.7% |
| 2017 Q3 | -0.07 USD | 8.89% |
| 2016 Q3 | -0.32 USD | 8.57% |
| 2016 Q2 | -0.35 USD | -9.37% |
| 2016 Q4 | -0.31 USD | 3.13% |
| 2016 FY | - USD | 16.25% |
| 2016 Q1 | -0.32 USD | 23.81% |
| 2015 Q4 | -0.42 USD | -55.56% |
| 2015 FY | - USD | -28.0% |
| 2015 Q3 | -0.27 USD | 47.06% |
| 2015 Q2 | -0.51 USD | -24.39% |
| 2015 Q1 | -0.41 USD | 2.38% |
| 2014 Q1 | -0.28 USD | 22.22% |
| 2014 Q4 | -0.42 USD | -90.91% |
| 2014 Q3 | -0.22 USD | 29.03% |
| 2014 Q2 | -0.31 USD | -10.71% |
| 2014 FY | - USD | 3.85% |
| 2013 Q1 | -0.33 USD | 13.16% |
| 2013 Q2 | -0.41 USD | -24.24% |
| 2013 Q3 | -0.23 USD | 43.9% |
| 2013 Q4 | -0.36 USD | -56.52% |
| 2013 FY | - USD | 31.58% |
| 2012 Q1 | -0.25 USD | 7.41% |
| 2012 FY | - USD | -331.82% |
| 2012 Q4 | -0.38 USD | 46.48% |
| 2012 Q3 | -0.71 USD | -42.0% |
| 2012 Q2 | -0.50 USD | -100.0% |
| 2011 FY | - USD | 51.11% |
| 2011 Q1 | -0.20 USD | 28.57% |
| 2011 Q2 | 0.40 USD | 300.0% |
| 2011 Q3 | -0.25 USD | -162.5% |
| 2011 Q4 | -0.27 USD | -8.0% |
| 2010 Q3 | -0.06 USD | 80.17% |
| 2010 Q4 | -0.28 USD | -386.96% |
| 2010 FY | - USD | 78.92% |
| 2010 Q1 | -0.26 USD | 55.93% |
| 2010 Q2 | -0.29 USD | -11.54% |
| 2009 FY | - USD | 38.21% |
| 2009 Q4 | -0.59 USD | -1.72% |
| 2009 Q1 | -1.87 USD | 7.43% |
| 2009 Q2 | -1.23 USD | 34.22% |
| 2009 Q3 | -0.58 USD | 52.85% |
| 2008 Q4 | -2.02 USD | -4.66% |
| 2008 Q3 | -1.93 USD | -31.29% |
| 2008 Q2 | -1.47 USD | -8.89% |
| 2008 Q1 | -1.35 USD | 31.12% |
| 2008 FY | - USD | 17.25% |
| 2007 Q2 | -1.80 USD | -66.67% |
| 2007 Q1 | -1.08 USD | 58.14% |
| 2007 FY | - USD | -40.34% |
| 2007 Q4 | -1.96 USD | 42.86% |
| 2007 Q3 | -3.43 USD | -90.56% |
| 2006 FY | - USD | -127.97% |
| 2006 Q3 | -1.18 USD | -21.65% |
| 2006 Q1 | -1.12 USD | -16.67% |
| 2006 Q2 | -0.97 USD | 13.39% |
| 2006 Q4 | -2.58 USD | -118.64% |
| 2005 Q3 | -1.62 USD | -505.0% |
| 2005 Q2 | 0.40 USD | 135.71% |
| 2005 Q1 | -1.12 USD | -3.7% |
| 2005 FY | - USD | -38.83% |
| 2005 Q4 | -0.96 USD | 40.74% |
| 2004 Q2 | -0.30 USD | 16.67% |
| 2004 Q4 | -1.08 USD | -129.79% |
| 2004 Q1 | -0.36 USD | -102.64% |
| 2004 FY | - USD | -652.0% |
| 2004 Q3 | -0.47 USD | -56.67% |
| 2003 Q3 | -6.49 USD | 50.04% |
| 2003 Q1 | -6.49 USD | 46.8% |
| 2003 FY | - USD | 99.23% |
| 2003 Q4 | 13.64 USD | 310.17% |
| 2003 Q2 | -12.99 USD | -100.15% |
| 2002 Q1 | -6.49 USD | -3.67% |
| 2002 FY | - USD | -25.03% |
| 2002 Q4 | -12.20 USD | 6.08% |
| 2002 Q3 | -12.99 USD | -1149.04% |
| 2002 Q2 | -1.04 USD | 83.98% |
| 2001 Q4 | -6.26 USD | -55.72% |
| 2001 FY | - USD | -33.32% |
| 2001 Q2 | -6.49 USD | 0.0% |
| 2001 Q1 | -6.49 USD | -217.36% |
| 2001 Q3 | -4.02 USD | 38.06% |
| 2000 Q1 | -6.49 USD | -29.8% |
| 2000 FY | - USD | -120.0% |
| 2000 Q4 | 5.53 USD | 185.21% |
| 2000 Q2 | -6.49 USD | 0.0% |
| 2000 Q3 | -6.49 USD | 0.0% |
| 1999 Q3 | 68.00 USD | 3500.0% |
| 1999 FY | - USD | 1058.66% |
| 1999 Q2 | -2.00 USD | 0.0% |
| 1999 Q1 | -2.00 USD | 0.0% |
| 1999 Q4 | -5.00 USD | -107.35% |
| 1998 Q2 | -1.00 USD | 0.0% |
| 1998 FY | - USD | 94.21% |
| 1998 Q3 | - USD | 100.0% |
| 1998 Q4 | -2.00 USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | -0.45 USD | -324.444% |
| Codexis, Inc. | -1.12 USD | -70.536% |
| Viridian Therapeutics, Inc. | -5.31 USD | 64.03% |
| Organovo Holdings, Inc. | -1.60 USD | -19.375% |